CA Stock MarketDetailed Quotes

BIOV BioVaxys Technology Corp

Watchlist
  • 0.060
  • -0.005-7.69%
15min DelayMarket Closed Jan 20 10:46 ET
15.72MMarket Cap-2.00P/E (TTM)

About BioVaxys Technology Corp Company

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Company Profile

SymbolBIOV
Company NameBioVaxys Technology Corp
Founded2018
MarketCNQ
Employees6
Fiscal Year Ends10-31
Address146 Thirtieth Street Suite 100
CityEtobicoke
CountryCAN
Zip CodeM8W 3D4
Phone+1 646 452-7054

Company Executives

  • Name
  • Position
  • Salary
  • James Passin
  • Chief Executive Officer and Director
  • --
  • David Wang
  • Director
  • --
Trending CA Stocks
Big Five Big Five

The "Big Five" refers to Canada's five largest banks—Royal Bank of Canada, Toronto-Dominion Bank, Bank of Nova Scotia, Bank of Montreal, and Canadian Imperial Bank of Commerce—which dominate and significantly influence the country's financial sector. The "Big Five" refers to Canada's five largest banks—Royal Bank of Canada, Toronto-Dominion Bank, Bank of Nova Scotia, Bank of Montreal, and Canadian Imperial Bank of Commerce—which dominate and significantly influence the country's financial sector.